From: Targeted therapy in advanced non-small cell lung cancer: current advances and future trends
KRAS inhibitors | ||||
---|---|---|---|---|
Drug name | Mechanism of action | Clinical trial (phase) | Study design | Disease |
Adagrasib (MRTX849) | KRAS G12C Inhibitor | NCT04330664 (1/2) | Combination with TNO155 | KRAS p.G12C mutant solid tumors including NSCLC |
Adagrasib (MRTX849) | Irreversible KRAS G12C Inhibitor | NCT04613596 (1/2) | Combination with Pembrolizumab | KRAS p.G12C mutant NSCLC with known PDL1 TPS score |
GDC-6036 | KRAS G12C Inhibitor | NCT04449874 (1) | Monotherapy | KRAS p.G12C mutant NSCLC |
D-1553 | KRAS G12C Inhibitor | NCT04585035 (1/2) | Monotherapy and combination with other standard therapies | KRAS p.G12C mutant NSCLC |
Rigosertib | RAS-mimetic | NCT04263090 (1/2) | Combination with Nivolumab | KRAS mutant NSCLC with progression on fist line therapy |
Sotorasib (AMG 510) | KRAS G12C Inhibitor | NCT03600883 (1/2) | Monotherapy | KRAS p.G12C mutant NSCLC |
Sotorasib (AMG 510) | KRAS G12C Inhibitor | NCT04303780 (3) | Monotherapy | KRAS p.G12C mutant NSCLC |